In Case You Missed It: From ISPOR Annual

Share on: 

While we certainly missed being able to engage in person with everyone at ISPOR, the virtual conference does provide an advantage: on-demand sessions that you can still access until June 30! 

As you’re checking out all the on-demand sessions, don't miss the presentations and posters from our experts.

Several of our researchers attended the Virtual ISPOR Annual Meeting and share some of their thoughts on the presentations they found particularly interesting.

When Is a QALY Not a QALY? Challenges in Introducing and Applying Modifiers in HTA Decision-Making
The presenters gave a summary of the NICE Methods Guide Update and noted that uncertainty is the only modifier which reduces the ICER threshold. The consequence being, to preserve price, companies need to minimize uncertainty in cost-effectiveness.
Sorrel Wolowacz, PhD
Head, European Health Economics

What Role Should HTA Play in the US Healthcare Marketplace? 
Presenters discussed developing a publicly funded organization to disseminate information on value and possibly to develop estimation methods–with an emphasis on evaluating all segments of the health care system–not just pharmaceuticals. The speakers described the rationale behind recommendations included in a report sponsored by the USC Schaeffer Center and the Aspen Institute for public funding of a US HTA body–interesting listening for anyone interested in US HTA policy.
Josephine Mauskopf, PhD
Vice President, Health Economics

Public Health Economics – Can We Model It? 
This was a complex session, but worth the effort to understand some of the modeling work being done to include the economic outcomes into pandemic modeling. Presenters addressed the impacts of the pandemic on research and various ways to mitigate its impact–including pharmaceutical and non-pharmaceutical interventions (both testing and tracing as well as vaccines and treatments) to capture both the effects on health and the economy. 
One speaker made the point that some decision-makers are familiar with these complex CGE models for estimating the impact of shocks to the economy, so the results of the pandemic impacts from such models might be credible to them. The key issue, addressed by the last speaker, was how to work with policymakers to develop policy driven by simulated results using these models.

Josephine Mauskopf, PhD
Vice President, Health Economics

Gene therapies: Reimbursement Challenges and Pricing Opportunities in the US 
This session was very informative. It started by overviewing the growth of gene therapies, went through the challenges faced by HTA and other reimbursement bodies, and ended with the discussion on the requirement of more standardization for assessing gene therapy and opportunities that exist for new data collection and innovative payment models.
Lei Ni
Decision Analytic Modeler/Research Health Economist

Network Meta-Analysis in HTA Submissions: Methodological Advances and Impact on HTA Methods Guidance 
This workshop’s presenters stated that because new methods are emerging at such a rapid rate, it is difficult to keep guidelines up to date. Two new methods were discussed, which have recently been referred to in the decision support unit guidelines (1) multi-level network meta-regression (ML-NMR) and (2) multivariate survival network meta-analysis. The first method, in particular, appears to be getting a great deal of interest.
Adrian Vickers, PhD
Director, Data Analytics and Design Strategy

Related Services:
Staff Members: